GlassScriptPhysician profile
Antwan Ahad
NPI 1083729917
$44,072.98
in general payments reported to CMS, 2019-2025
79 companies · $7,515 in 2025
The $7,515 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,527 · 2020: $3,227 · 2021: $5,972 · 2022: $7,783 · 2023: $7,204 · 2024: $7,845 · 2025: $7,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,563.32 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,637.99 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Emd Serono, INC. | $4,156.32 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $3,307.10 | 2019-2025 | Vumerity, Tysabri, Qalsody |
| Lundbeck LLC | $2,082.60 | 2019-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $1,635.00 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $1,561.81 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amneal Pharmaceuticals LLC | $1,541.27 | 2019-2025 | Crexont, Rytary, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,496.62 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,244.83 | 2019-2025 | Ultomiris |
| Pfizer INC. | $1,175.40 | 2020-2025 | |
| Celgene Corporation | $1,099.92 | 2021-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $968.42 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $919.50 | 2020-2025 | Ingrezza, Ongentys |
| Eisai INC. | $916.32 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $888.12 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $877.80 | 2019-2025 | Briviact, Nayzilam |
| Axsome Therapeutics, INC. | $819.39 | 2024-2025 | Symbravo, Sunosi, Auvelity |
| Sumitomo Pharma America, INC. | $660.73 | 2023-2024 | Aptiom |
| Neurelis, INC. | $623.83 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $610.21 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $607.52 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $562.89 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Scilex Pharmaceuticals INC. | $544.98 | 2020-2025 | Ztlido |
| Amgen INC. | $532.50 | 2019-2025 | Uplizna |
| Medtronic, INC. | $460.84 | 2022-2024 | Visualase, Percept PC Brainsense |
| Allergan, INC. | $454.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $431.60 | 2023-2025 | Rexulti, Nuedexta |
| Genzyme Corporation | $418.57 | 2019-2021 | |
| Mdd US Operations, LLC | $411.86 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $405.62 | 2019-2022 | |
| Tg Therapeutics, INC. | $399.98 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $395.77 | 2019-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $388.93 | 2021-2023 | Ponvory |
| Csl Behring | $378.06 | 2019-2025 | Hizentra |
| Avadel Cns Pharmaceuticals, LLC | $374.97 | 2024-2025 | Lumryz |
| Kyowa Kirin, INC. | $371.58 | 2020-2024 | Nourianz |
| Monteris Medical Corporation | $364.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $357.58 | 2022 | |
| Novocure INC. | $317.77 | 2024 | Optune |
| Impel Pharmaceuticals INC. | $316.66 | 2022-2023 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $303.14 | 2021-2024 | Wainua |
| Acorda Therapeutics, INC | $272.52 | 2019-2024 | Inbrija |
| Ani Pharmaceuticals, INC. | $236.34 | 2022-2024 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $226.66 | 2021-2023 | Gralise |
| Grifols USA, LLC | $220.90 | 2019-2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $212.08 | 2023-2025 | Horizant, Horizant |
| Jazz Pharmaceuticals INC. | $202.51 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $194.90 | 2020-2021 | |
| Abbott Laboratories | $186.89 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $183.55 | 2020-2021 | |
| Ge Healthcare | $179.37 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $148.85 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $140.25 | 2021 | |
| Vanda Pharmaceuticals INC. | $137.71 | 2024 | Ponvory |
| Imperative Care, INC | $134.29 | 2025 | Zoom 88-T Large Distal Platform |
| Noctrix Health, INC. | $125.32 | 2025 | Nidra |
| Philips North America LLC | $119.66 | 2022 | |
| Octapharma USA, INC. | $107.10 | 2022-2025 | Panzyga |
| Upsher-Smith Laboratories LLC | $87.27 | 2020-2023 | |
| Banner Life Sciences, LLC | $87.06 | 2021-2024 | |
| Horizon Therapeutics Plc | $84.05 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $80.56 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $75.46 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $71.38 | 2020-2022 | |
| Aquestive Therapeutics, INC. | $64.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $64.51 | 2020-2021 | |
| Aucta Pharmaceuticals, INC. | $54.71 | 2024-2025 | Motpoly Xr |
| Zyla Life Sciences, INC. | $53.44 | 2019-2020 | |
| Livanova USA, INC. | $48.20 | 2019 | |
| Avion Pharmaceuticals | $40.36 | 2023 | Dhivy |
| Grt US Holding, INC. | $34.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.38 | 2023-2025 | Hyqvia, Trintellix |
| Bausch Health US, LLC | $28.99 | 2021 | |
| Medtronic USA, INC. | $28.02 | 2019 | |
| Boston Scientific Corporation | $24.20 | 2019 | |
| Metacel Pharmaceuticals LLC | $19.19 | 2025 | Ozobax |
| Ironwood Pharmaceuticals, INC | $18.83 | 2021 | |
| Endo Pharmaceuticals INC. | $14.18 | 2019 | |
| Amarin Pharma, INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antwan Ahad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.